SRR1321046
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.318
- OXIDATIVE_PHOSPHORYLATION+0.314
- FATTY_ACID_METABOLISM+0.306
- BILE_ACID_METABOLISM+0.295
- PANCREAS_BETA_CELLS+0.261
- SPERMATOGENESIS+0.227
- ADIPOGENESIS+0.195
- COAGULATION+0.166
- XENOBIOTIC_METABOLISM+0.151
- ESTROGEN_RESPONSE_LATE+0.149
Top 10 suppressed
- MYC_TARGETS_V2-0.387
- MITOTIC_SPINDLE-0.384
- HEDGEHOG_SIGNALING-0.352
- WNT_BETA_CATENIN_SIGNALING-0.344
- UNFOLDED_PROTEIN_RESPONSE-0.335
- IL6_JAK_STAT3_SIGNALING-0.289
- TNFA_SIGNALING_VIA_NFKB-0.276
- G2M_CHECKPOINT-0.267
- ANGIOGENESIS-0.263
- NOTCH_SIGNALING-0.252
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1474466 | GTEX | — | 0.907 |
| 2 | SRR1433750 | GTEX | — | 0.882 |
| 3 | SRR1323764 | GTEX | — | 0.864 |
| 4 | SRR1435293 | GTEX | — | 0.847 |
| 5 | SRR1315371 | GTEX | — | 0.841 |
| 6 | MNG764 | — | — | 0.829 |
| 7 | BS_9DZ253JY | pilocytic astrocytoma | — | 0.828 |
| 8 | SRR1410656 | GTEX | — | 0.825 |
| 9 | SRR1318426 | GTEX | — | 0.820 |
| 10 | SRR1458044 | GTEX | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.318 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.314 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.306 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.295 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.261 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.227 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.195 | Inavolisib | — uncovered |
| COAGULATION | 0.166 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.151 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.149 | Idelalisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.076 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.037 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.031 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.015 | Inavolisib | — uncovered |